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METHODS: A group of practitioners with expertise and experience in sarcoma BT formulated
recommendations for BT in STS based on clinical experience and literature review.
RESULTS: The indications for adjuvant BT are discussed. There is no consensus on the use of BT
alone or in combination with external beam radiation therapy (EBRT), but factors that influence the
selection of this modality include tumor grade and size, prior surgeries, and tumor recurrence. Low-
dose-rate, high-dose-rate, and pulsed-dose-rate radiation are all acceptable BT modalities to use for
STS. Recommendations are made for patient selection, techniques, dose rates, and dosages.
Outcome data and toxicity data are reviewed.
CONCLUSIONS: BT is a useful component of the treatment of STS. The advantages of BT are
the targeted dose distribution, low integral dose, and short treatment times. Ultimately the clinician
should select the modality or combination of modalities that are most familiar to the treatment team
and suitable to the patient.  2013 American Brachytherapy Society. Published by Elsevier Inc.
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Soft tissue sarcomas (STSs) may occur anywhere in the
body, including the extremities, trunk, and head and neck.
There are many pathologic types and histologic grades with
different natural histories. Surgery is the preferred primary
treatment in most cases. Radiation and chemotherapy are
important treatments that are typically supplemental to
curative surgery. Alternatively, they may be applied with
curative or palliative intent for unresectable lesions or inop-
erable patients. The primary goal of treatment is cure of theember 2012; received in revised form 2 December
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.1016/j.brachy.2012.12.002disease with preservation of the structure and function of
the affected body part or organ. Conservative surgery has
generally replaced amputation as the treatment of choice
for extremity sarcomas because it better accomplishes these
dual objectives (1e3). The combination of wide local exci-
sion (WLE) with pathologically clear margins and radiation
therapy is the preferred therapy in most patients. Selected
cases with lesions less than 5 cm, particularly if superficial
and low grade, may be considered for surgery alone (4, 5).
The use of adjuvant external beam radiation therapy
(EBRT) or brachytherapy (BT) to enhance local control
(LC) in patients undergoing limb-sparing sarcoma resec-
tions in the extremity is supported by Level 1 evidence
from randomized prospective clinical trials (6, 7).
Radiation therapy may be administered as preoperative
external beam or postoperatively as either EBRT or BT.
There are no controlled studies comparing EBRT with
BT. Implant catheters are typically inserted at the time of
surgical excision, which allows directed catheter placementOpen access under CC BY-NC-ND license.
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(OARs). BT provides high radiation doses to the tumor
bed and lower doses to tissues outside the implanted
volume. If the target is localized to a region that can be en-
compassed with catheters, BT can be used as the sole
therapy (8), although some data suggest improved outcome
with a combination of BT and EBRT for patients with posi-
tive margins (9, 10). Source delivery can be done as low
dose rate (LDR) as an inpatient or high dose rate (HDR)
either as inpatient or outpatient depending on the medical
and surgical care needs of the patient. In either case, BT
courses are relatively short and convenient for patients.
The limitations for BT in the treatment of sarcomas are
the commonly large target volumes, restrictions in catheter
placement because of bone or visceral organs, anatomic
sites where good catheter geometry may be difficult to
achieve (i.e., around the shoulder), and risk of radiation
injury to nerves that are in direct contact with the BT
catheters.Methods and materials
A group of practitioners with expertise and experience
in sarcoma BT were appointed by the American Brachy-
therapy Society (ABS) Board of Directors to provide
a consensus statement for the use of BT in STS.
The previously published ABS guidelines were updated
with a literature search, and the experts view on the state of
the art was formulated. The evidence supporting BT as
a component of the multidisciplinary management of
sarcoma is described. Recommendations are made on radi-
ation techniques and doses, and the expected tumor control
and complication rates are provided. This consensus state-
ment was submitted to the ABS Board of Directors for
approval before publication.Results
Patient selection
Ideally, patients should be evaluated by a multidisci-
plinary sarcoma team, which includes surgical, radiation
and medical oncologists, radiologists, and pathologists with
knowledge and experience in the management of sarcomas.
Preoperative staging evaluations include careful examina-
tion of the affected body site for extent of disease and the
functional status of the affected body structure followed
by imaging of the tumor with MRI for pelvic, extremity,
and truncal lesions and CT for abdominal and retroperito-
neal lesions to determine the radiologic extent of disease.
Preoperative imaging delineates the gross disease and asso-
ciated tissue edema, and it may reveal invasion into
surrounding structures. Identification of the relationship
of the lesion to adjacent critical structures, such as bone,
nerves, and blood vessels, can be used to plan the extentand nature of the surgery. It is equally important to consider
whether skin, soft tissue, bone, or vascular grafting will be
required to repair the surgical defect.
Chest CT should be obtained to rule out lung metastasis,
which is the most common site of distant spread; patients
with low-grade T1 lesions can be adequately staged with
a chest X-ray. CT of the abdomen and pelvis may be valu-
able for patients with extremity or truncal liposarcoma,
epithelioid sarcoma, angiosarcoma, or leiomyosarcoma,
which have a higher rate of extrapulmonary spread (11).
PET/CT may be useful for histologies with a predilection
for nodal metastases, including clear cell sarcoma, angio-
sarcoma, rhabdomyosarcoma, epithelioid sarcoma, and
synovial sarcoma. MRI of the spine for patients with myx-
oid liposarcoma can also be considered (12). Detection of
lung metastasis should prompt consideration of chemo-
therapy and possibly surgical resection depending on
the number, location, size, and rapidity of progression
(13e15). Metastectomy for non-pulmonary metastasis has
also been reported (16e18).
Treatment modality
Surgery
Patients with small (!5 cm) superficial tumors or small
deep tumors that can be resected with wide margins (O1
cm) or complete resection with the investing fascial barriers
are candidates for surgery without radiation therapy (4, 5, 19).
Radiation
The indications for radiation therapy are those features
that put the patient at risk for local recurrence after surgical
resection. These factors include narrow or positive surgical
margins, local recurrence after prior surgery, tumor size
ofO5 cm, lesions deep to or invading the superficial fascia,
high grade, and younger than 50 years (20).
BT monotherapy as an adjuvant can be considered in
patients with high-grade sarcomas of the extremity or super-
ficial trunk if they have undergone complete surgical exci-
sion with negative margins (8). There is no consensus on
whether BT should be combined with EBRT in the setting
of positive margins or whether one modality is sufficient.
Early data from Memorial Sloan-Kettering Cancer Center
(MSKCC) showed that combined BT and EBRT had better
LC for patients with positive margins (9), but in subsequent
reports that difference was not observed (21). Factors that
may influence the use of EBRT and BT in scenarios with
positive margins include the tumor grade, prior surgeries,
and tumor size (22). BT in combination with external beam
is recommended for cases with recurrent disease who have
not been previously irradiated (10, 23e25).
Location
The location of the primary sarcoma appears to impact
the clinical outcome, and it may affect treatment planning
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there may be differences in tumor control rates and
morbidity between upper and lower extremity lesions as
well as extremity vs. truncal lesions. The MSKCC group
evaluated patients treated with either EBRT or BT and
found that the upper extremity was associated with a greater
rate of local recurrence compared with the lower extremity
(26) independent of tumor size, depth, and margin status.
Their group also noted the shoulder location as an indepen-
dent prognostic factor for poor LC (8). Several BT series
report increased toxicity in the lower limb compared with
the upper limb (23, 27, 28). Sensitive locations such as
the hands also have increased toxicity with radiation
compared with surgery alone. In a retrospective review of
55 patients with STS of the hands, 26 had radiation with
EBRT alone (21 patients) or combined with BT (5 patients).
The complication rate was higher in the radiation cohort
compared with the surgical cohort (19/26 vs. 3/29), and
all 5 patients who underwent BT developed complications.
The placement of BT catheters adjacent to finger joints
seemed to be associated with complications (29). These
studies indicate that for distal extremity (acral) lesions
meticulous attention to treatment technique is warranted.
The clinical circumstances, implant volume, target dose,
timing of treatment, and other technical details of BT can
have significant impact on outcome and must be carefully
assessed before treatment.
The interstitial implant procedure
The most common method used for the treatment of
STS is the placement of interstitial BT catheters at the
time of surgical excision of the tumor where the surgical
and radiation oncologists together define the tumor bed
and target volume. The reason for intraoperative catheter
placement is two-fold. First, the extent of the primary
tumor is most apparent during surgery. The radiation
target can be determined with both surgical and radio-
logic information. Second, the location of critical normal
structures, such as bone, blood vessels, and nerves, affects
the placement of the implant catheters, and their locations
should be considered during the radiation treatment plan-
ning. Bones generally limit catheter placement so accom-
modation of bony anatomy is necessary. Penetration of
arteries and veins and direct contact of BT catheters with
nerves are to be avoided. Although peripheral nerves are
generally tolerant to radiation, the very high doses of
radiation adjacent to the sources may be injurious.
Measures such as delineation of the course of the nerve
in relationship to the implant sources or placement of
spacers (e.g., gelfoam or temporary drains) between the
catheters and the nerve are important procedural consid-
erations. The placement of radio-opaque markers or clips
is useful to demarcate the tumor bed target and the critical
structures so they can be better identified during treat-
ment planning.Target volume
The target volume should consist of the surgical bed
from which the tumor was excised plus a margin. The scar
and drain sites are typically not targeted. There is no
consensus on the size of the radiation treatment margin,
and various prognostic factors, such as tumor size, resection
quality, histology, may impact the judgment about the treat-
ment volume. Other factors influencing the margin include
natural anatomic boundaries, adjacent normal tissue dose
constraints, potential seeding from prior procedures, and
whether BT is used as monotherapy or in combination with
EBRT (30). In general, at least 2 cm craniocaudally and
1e2 cm radially are recommended (30, 31).Catheter placement
Interstitial implants are performed by passing hollow
needles through the skin and soft tissue. The distance from
the wound incision to the catheter entry point should be at
least 1e2 cm. The needles are then replaced with one of the
several kinds of BT catheters. The configuration of the
implant must be individually tailored to the clinical circum-
stances. In general, the target is a volume of tissue rather
than just a surface. Single-plane implants can be used if
there is complete gross tumor removal (i.e., R0/R1 resec-
tion) and fascial plane barriers permit omission of deeper
catheters or bone prevents additional catheter placement.
Gross residual tumor must be encompassed by a volume
implant to achieve optimal dosimetry. The number of BT
catheters and the volume of the implant can vary widely de-
pending on the size and location of the lesion. Catheters
should be placed with the recommended craniocaudal and
radial margins. Lesions of the hands and feet would be
customized to accommodate smaller volumes and margins.
Catheters may be placed either parallel or perpendicular
(Fig. 1) to the incision although mixtures with crossed ends
can be useful. Parallel catheters usually are fewer and
longer than perpendicular catheter arrays and may be most
appropriate when the tumor bed contour follows the curva-
ture of the extremity. Catheters and planes of catheters are
placed at 1e1.5-cm intervals to ensure adequate dosimetry.
Single-plane implants generally require closer spacing than
multiplane volume implants to avoid scalloping of the
prescription isodose. It is important to understand that
wound closure can affect the catheter configuration through
traction and bending as tissues are opposed and sutured
together. The wound closure and catheter placement, there-
fore, must be done in concert to achieve satisfactory
coverage of the clinical target volume (CTV).
Catheter stabilization is essential for quality treatment
delivery. Catheters can be sutured directly into the surgical
bed with absorbable sutures and are also anchored to the
external skin surface with various devices such as fixing
buttons. Another stabilization and spacing method is to
thread the implant catheters through JacksonePratt drains
Fig. 2. Multiplane high-dose-rate radiation brachytherapy implant. The
drain remains in situ until the implant is ready to be pulled at the comple-
tion of the brachytherapy course.
Fig. 1. Intraoperative placement of brachytherapy catheters demonstrating both (a) parallel and (b) perpendicular orientation of the catheters in relation to
the wound. (b) JacksonePratt drains are used to immobilize the implant.
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drains are oriented perpendicular to the catheters that pass
through the drain holes to create a stable implant unit
(Fig. 1) (32). Catheters may be open at one (single leader)
or both (double leader) ends, if they run from skin to skin,
or they may be blind ended and terminate within
the wound. Stabilization of blind-ended tubes is more
difficult than for skin-to-skin catheter arrangements. The
JacksonePratt technique fixes the blind-ended tubes
within the wound and helps prevent postoperative catheter
displacements.
Tissue expanders can be used to protect normal struc-
tures from high exposure rates from the radiation sources.
Gelfoam, drains, or inflatable (removable) materials can
be placed between the catheters and critical structures to
prevent normal tissue injury in the very highedose region.
The radiation oncologist must consider the effect of tissue
expanders on target coverage during simulation and dosim-
etry calculations.
Catheter care and loading
Once the catheters are placed and the wound is closed, it
is important to check the relationship of the catheters to the
wound and ensure that there is sufficient space (~0.5 cm)
between the catheter buttons and the skin to allow for post-
operative swelling. The implant should be oriented so the
catheters exit the skin in such a way as to easily insert
the radiation source. Drains placed at the time of surgery
should not be removed (Fig. 2) until after the BT is
completed and the implant catheters are taken out to
prevent inadvertent displacement of the catheters. This
measure may also help decrease the risk of developing
a seroma.
Simulation and dosimetry
BT catheters generally come with an internal leader that
helps to prevent the catheters from stretching as they are
pulled through the tissue during insertion. Before simula-
tion, the internal leader of the catheters is removed and re-
placed with markers called ‘‘dummy ribbons,’’ which help
to identify the potential source positions. The implantcatheters should be individually numbered for correct iden-
tification during source loading. The position of the cath-
eter at the skin should also be marked for future
reference during treatment delivery to ensure that the cath-
eter depth has not changed between treatments.
CT simulation is the current standard for BT dosimetry
of sarcomas. It allows for three-dimensional dosimetry of
the implant. The radio-opaque markers or clips placed at
the time of surgery help the physician contour the CTV.
Presentation of axial isodose curves, doseevolume histo-
gram (DVH) data, and virtual images facilitates under-
standing of the target doses and permits placement of
dose constraints on normal tissue (Fig. 3). In BT, the
CTV and planning treatment volumes are ideally
congruous. The quality of the implant can be measured in
terms of D90 (dose to 90% of the CTV), V100 (percent of
the CTV that receives the 100% isodose), V150 (percent
of the CTV that receives the 150% isodose), or similar
measures. Normal tissue dose constraints are typically
derived from the DVH data, which are represented as doses
to various volumes, such as D0.1cc, D1cc, and D2cc. An
attempt should be made to limit the dose to the surgical
incision to less than 100% isodose unless it is considered
at high risk for tumor involvement. The dose to the skin
Fig. 3. Three-dimensional CT-based dosimetry of a brachytherapy implant as seen in (a) coronal and (b) axial planes. The 150e50% isodoses are demon-
strated. (b) Surgical clips help to delineate the clinical target volume.
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two-thirds of the prescribed dose. In addition, source
loading should be no closer than 0.5 cm from the skin
surface to minimize skin toxicity. There are limited data
in the literature to equate DVH parameters with LC or
toxicity outcomes.
Treatment delivery
Once dosimetry is completed, the prescription dose can
be delivered to the CTV.
Treatment can be administered as an inpatient with LDR
manual loaded sources (most commonly iridium-192 [192Ir]
seeds embedded in ribbons). Radiation safety precautions
related to time of exposure, distance, and shielding are
needed on the wards, where the patients are confined for
the duration of the implant. Alternatively, HDR remote
afterloading may be selected. It has the advantage of avoid-
ing radiation exposure to personnel, and for many
sarcomas, the treatment can be given as an outpatient. In
LDR dosimetry, the median peripheral dose rate, defined
as the lowest continuous isodose rate line that covers the
CTV (usually ~0.45 Gy/h), is identified. This is generally
5 mm from the plane of the implant. The dosimetry for
CT-based HDR is optimally volume based as described,
or it can also be calculated at a point 5 mm from the cath-
eters. Pulsed dose rate (PDR), a hybrid source delivery
method that involves remote afterloading in short bursts
at hourly doses at rates, is thought to be radiobiologically
comparable to LDR. Regardless of the source delivery
method, the patency, position, and integrity of the implant
catheters should be verified daily during LDR treatment
delivery and before each remote afterloading treatment.
It is recommended that the patient be clinically assessed
for surgical complications before source delivery. Imme-
diate postoperative complications, such as hemorrhage, se-
roma, wound breakdown, dehiscence, or infection, may
delay loading of radiation and necessitate repeat treatment
planning. Typically, 5 days is allowed to elapse for wound
healing before treatment starts depending on the extent and
location of the surgery and the relationship of the implant
to the wound closure. 192Ir source loading (LDR or HDR)has been described in the literature between postoperative
Day 2e4 (33) and Day 5e8 (7). MSKCC found decreased
toxicity with loading Day 5 or more (34).
Catheter care and removal
The surgical wound and implant catheters should be kept
as clean and dry as possible. This objective may be accom-
plished by the application of sterile dressing between
cleansings. The patient should avoid showering, bathing,
or wetting the implant catheters except during wound care.
Antibiotic ointment may be applied sparingly at the cath-
eter entrance and exit sites. Catheter removal should be in
as clean a fashion as possible. In the removal of double
leader implants, the catheters should be sterile prepared
on the side that will be cut at the skin surface. The skin
should then be depressed slightly so the catheter can be
cut in a way to avoid pulling the external aspect of the cath-
eter through the wound.
Treatment results according to dose rate: LDR, HDR,
and PDR
Low dose rate
Dose rate is an important consideration in BT. Interstitial
catheter BT for STS has used LDR iridium wires or seeds
in ribbons that are loaded manually in the catheters. A
randomized study (7) and a number of prospective and
retrospective reports have evaluated LDR BT either as
monotherapy or in combination with EBRT (9, 22, 35e43).
LC after LDR monotherapy is reported between 66%
and 96% and LDR BT and EBRT between 78 and 100%.
The complication rates are also comparable with reopera-
tion rates of 10e12% for monotherapy and 2.3e13.8%
for BT and EBRT (Table 1). Alekhteyar et al. (9) evaluated
105 patients who underwent WLE followed by LDR BT vs.
LDR BT and EBRT. They did not find a significant differ-
ence in 2-year LC between the cohorts (90% vs. 82%) but
a trend for improved LC in patients with positive margins
who had BT and EBRT compared with BT alone (90%
vs. 59%, p 5 0.08). There was no difference in wound
complication rate (26% vs. 38%). Laskar et al. (44)
Table 1
LC and complication rates of selected LDR and PDR BT series
First author Year FU (mo) Modality n LC (%) ComplicationsO grade 2 (%)
Alekhteyar (9) 1996 22 LDR BT 87 82 16
LDR BT þ EB 18 90 27
Pisters (5) 1996 76 LDR BT 56 82 14
Chaudhary (43) 1998 40 LDR BT 33 75 1
LDR BT þ EB 118 71
Delannes (38) 2000 54 LDR BT 58 89 17
Alektiar (8) 2002 61 LDR BT 202 84 12
Rosenblatt (39) 2003 36 LDR BT 9 87.5 16
LDR BT þ EB 21
Andrews (22) 2004 69 EB 61 83 8
LDR BT þ EB 25 90
Lazzaro (51) 2005 34 PDR BT 18 88 7
PDR BT þ EB 24 92
Llacer (28) 2006 58 LDR BT 6 90 45
LDR/PDR BT þ EB 73
Laskar (42) 2007 45 LDR/HDR BT 54 61 5a
LDR/HDR BT þ EB 100 83 30a
Mierzwa (41) 2007 39 LDR BT 24 79 4
LDR BT þ EB 19 100 21
Beltrami (40) 2008 75 LDR BT þ EB 112 87 12.5
Muhic (52) 2008 41 PDR BT þ EB 39 83 21
LC 5 local control; LDR 5 low dose rate; PDR 5 pulsed dose rate; BT 5 brachytherapy; FU 5 followup; EB 5 external beam radiation.
a Wound fibrosis.
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then either BT or BT and EBRT. They found LC to be
comparable (78% vs. 84%, p 5 0.89).
Andrews et al. (22) reported on 86 patients treated with
EBRT alone (61 patients) or in combination with BT (25
patients). The decision to use BT was based on a perceived
risk of microscopically positive margins. There was no
difference in 5-year overall survival (OS) (82% vs. 72%,
p 5 0.93) or LC (90% vs. 83%, p 5 0.15). However, in
univariate analysis of Stage III patients, the LC was
improved if treated with EBRT and BT (100% vs. 62%,
p5 0.03). Also high-grade lesions tended to have improved
LC with EBRT and BT (100% vs. 74%, p 5 0.09). No
factors predicted for improved LC on multivariate analysis,
possibly because of the small sample size. In a review by
Laskar et al. (42), 155 patients (98 treated with LDR and
57 with HDR) had WLE of the primary tumor with BT
alone (55 patients) or with EBRT (100 patients). In their
cohort, the disease-free survival (DFS) and OS were supe-
rior in superficial tumors less than 5 cm. Dose greater than
60 Gy was found to favorably impact LC, DFS, and OS.
They found fewer complications with BT monotherapy
compared with BT and EBRT.
The justification for LDR BT for STS rests on these
outcome reports and is supported by radiobiologic theory,
which predicts for tumor control and normal tissue toler-
ance when sufficient and properly distributed radiation
doses are applied. The limitations of LDR are radiation
exposure to personnel, patient isolation for prolonged
periods, limitations on nursing care, and potential for
unrecognized catheter or source displacement.High dose rate
HDR BT with remote afterloading has become increas-
ingly prevalent (Table 2) because of improved radiation
safety and better control of the dose distributions associated
with a stepping source. There are several reports on HDR
monotherapy (10, 24, 45e48). Itami et al. (24) reported
on 25 patients (26 lesions) treated with 36 Gy in six frac-
tions of HDR (a dose that would be predicted to control
microscopic disease). Their overall 5-year local regional
control was 78%. LC in patients with positive margins
and previous surgical resections was only 43.8% compared
with 93% for patients with negative margins and no
previous resections. All local recurrences were outside the
treated volume. They concluded that EBRT should be
added for patients with previous surgery or positive margins
as most of the recurrences would have fallen within a tradi-
tional EBRT volume. Koizumi et al. (47) reported on 16
lesions treated with HDR 40e50 Gy in 7e10 fractions over
4e7 days twice a day (BID) prescribed at 5 or 10 mm from
the source. LC was 50%. Of the eight uncontrolled lesions,
63% had macroscopically positive resection margins that
may explain the relatively low LC rate. Although not
strictly comparable to results in adults, Nag et al. (48) re-
ported 80% long-term LC in children treated with HDR
monotherapy (36 Gy in 12 fractions) with 20% Grade
3e4 long-term complications.
Most of the reported HDR experience is with combined
EBRT (10, 23, 25, 39, 46, 49, 50). Petera et al. (10) retro-
spectively reviewed 45 patients with primary or recurrent
STS who either underwent HDR monotherapy (30e54
Gy) or HDR (15e30 Gy) and EBRT (40e50 Gy). The
Table 2
LC and complication rates of selected HDR BT series
First author Year FU (mo) Modality n LC (%)
Complications
OGrade 2 (%) Reoperation (%)
Koizumi (47) 1999 30 HDR BT 16 50 6 NR
Itami (24) 2010 50 HDR BT 26 78 11.5 7.7
Chun (25) 2001 31 HDR BT þ EB 17 100 NR 6
Martinez-Monge (49) 2005 23 HDR BT þ EB 25 23 28 NR
Aronowitz (50) 2006 34 HDR BT þ EB 12 83 NR 25
Petera (10) 2010 38 HDR BT 11 55 4.4 2
HDR BT þ EB 34 85
San Miguel (23) 2011 49 HDR BT þ EB 60 77.4 28.3 10
Emory (46) 2012 11 HDR BT 37 92 NR 22
HDR BT þ EB 12 83 NR 33
LC 5 local control; HDR 5 high dose rate; BT 5 brachytherapy; FU 5 followup; NR 5 not reported; EB 5 external beam radiation.
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gist. They reported 100% LC for primary tumors compared
with 64% for recurrent tumors. LC was superior for
extremity lesions compared with trunk tumors and HDR
and EBRT compared with BT alone (odds ratio 5 0.21;
95% confidence interval: 0.026, 0.651, p 5 0.013). LC
was also improved with doses greater than 65 Gy. A Japa-
nese group reported their experience of HDR and EBRT.
Their inclusion criteria were (1) high tumor grade, (2)
low-grade tumor $10 cm, (3) recurrent tumor, (4) tumor
abutting or invading critical structures, and (5) positive
margins. They prescribed 2e3 Gy/fraction  6, BID
combined with EBRT (36e60 Gy). After a median follow-
up of 31 months, there was no local failure within the radi-
ation field (25). San Miguel et al. (23) combined 45 Gy of
EBRT with 16 or 24 Gy HDR BT depending on the margin
status. LC at 9 years was reported as 77.4%. Positive
margins had a 4.4-fold risk of local failure compared with
close or negative margin ( p 5 0.036). They report 30%
Grade 3e4 toxic events, with the majority related to wound
healing. Despite this relatively high rate of toxicity, the re-
operation rate was comparable to other series at 10%.
Lower limb location and volume of the 150% isodose
(TV150O27 mL) combined predicted for Grade 3 complica-
tions ( p 5 0.003).
There is no randomized comparison of HDR and LDR
BT. Pohar et al. (27), however, published a historical
control comparison in 37 patients treated between 1995
and 2004. Twenty-seven patients had LDR and 17 patients
HDR (since 2001). The mean EBRT dose was approxi-
mately 50 Gy. The LDR dose was 15 Gy prescribed at 6-
mm depth (0.42 Gy/h) based on the Paris system of loading.
The mean HDR dose was 13 Gy (10.2e18 Gy) over three to
four fractions BID. They noted an increase in toxicity in
patients receiving O15 Gy HDR and adopted a standard
HDR dose of 4.5 Gy  3 (13.5 Gy). LC was 90%
with LDR and 94% for HDR. There was a trend of
decreased occurrence of severe complications (Grade
3e4) in the HDR group (30% LDR vs. 6% HDR
p 5 0.06). Laskar et al. (44) retrospectively reviewed their
pediatric data for patients who underwent WLE with BTwith or without EBRT. Both LDR and HDR were in their
cohort. Of 50 patients, 30 had BT alone (LDR or HDR).
They concluded that LC related to size of tumor and grade
(better control for tumors !5 cm and low-grade tumors).
LC for BT and EBRT was comparable to BT alone (78%
vs. 84%, p 5 0.89), and there was no difference in LC
between LDR and HDR either as monotherapy or in combi-
nation with EBRT (77% vs. 92%, p 5 0.32; 67% vs. 100%,
p 5 0.17).
We concluded, therefore, that HDR is also a valid
approach to source loading for STS. The radiobiology of
large fraction sizes and the potential for creative combina-
tions of HDR BT with systemic therapy is yet to be
explored. HDR has some functional and radiation safety
advantages for pediatric patients.
Pulsed dose rate
There are a limited number of reports on the use of PDR
BT in STS (28, 51, 52). The LC and toxicity appears
consistent with LDR treatments with reported local
regional control rates of 83e90% at 5 years, despite the
large number of cases with positive margins (19e45.6%).
In the study by Llacer et al. (28), LDR or PDR as mono-
therapy (45 Gy) or in combination with EBRT (20 Gy
BT and 45 Gy EBRT) was used. All tumors involved the
neurovascular structures (45.6% positive margins). The 5-
year LC was 90%. Late complications related to lesion
location in the lower limb, the number of catheters, and
treatment thickness of 20 mm or more. They did not eval-
uate a difference between the two techniques. Muhic et al.
(52) reported a reoperation rate of 10% for patients
receiving 20 Gy PDR and 50 EBRT. This result is compa-
rable to reports in the LDR literature. Therefore, PDR is
also considered a suitable source loading method for STS.
Dose rate summary
All the described BT dose rate delivery systems, with
their various advantages, are valid alternatives (Table 3).
Studies are not available to separate outcome benefits for
one dose rate over another. The extent of the disease,
quality of the implant, case selection, and use of external
Table 3
Recommended BT prescription doses for primary STS treatment
Modality EB (Gy) BT (Gy) Days Comment
LDR BT 45e50 4e6 0.45e0.5 Gy/h
LDR BT þ EB 45e50 15e25 2e3 0.45e0.5 Gy/h
HDR BT 30e54a 4e7 2e4 Gy BIDb
HDR BT þ EB 45e50 12e20 2e3 2e4 Gy BID
PDR BT 45e50 2e3 0.45e0.5 Gy/h
PDR BT þ EB 45e50 15e25 3e4 0.45e0.5 Gy/h
BT 5 brachytherapy; STS 5 soft tissue sarcoma; EB 5 external beam
radiation; LDR 5 low dose rate; PDR 5 pulsed dose rate; HDR 5 high
dose rate; BID 5 twice a day; Gy 5 gray.
a HDR monotherapy included patients with positive margins or recur-
rent disease.
b Several authors recommend 6-hour intervals for BID HDR BT
(46, 47).
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variables.
Complications/safety
The impact of BT on acute and chronic complications is
somewhat unclear because treatment is usually multimodal.
Factors that influence the complication rates include tumor
stage, disease location, the nature and extent of the resec-
tion, and previous or planned EBRT or chemotherapy.
Wound complication rates range from 7% to 59% (10,
21, 23, 24, 27, 28, 38, 42, 51, 52). Delayed wound healing
is the most common acute complication. The MSKCC
randomized trial reported no significant difference in the
wound complication rate as a consequence of BT (24%
BT vs. 14% no BT; p 5 0.13), but the rate of wound reop-
eration was significantly higher in the BT arm (10% vs. 0%;
p 5 0.006) (34). The rate of reoperation reported in the
literature is 2.3e13.8% (23). Strategies to decrease wound
healing complications include waiting for several days
before source loading and the use of free flaps to decrease
the wound tension (53, 54). The literature indicates that BT
is safe when performed in association with free tissue trans-
fer (55e58).
Wound complication rates after LDR BT are affected by
various factors such as time to source loading more than 5
days (34) and good implant geometry (27), which are both
associated with lower morbidity. The number of BT cathe-
ters or wires (O10) and treatment thicknessO20 mm have
also been reported to impact on vascular toxicity (28).
Toxicity associated with HDR appears to be related to total
radiation dose, total BT dose, HDR fraction size, and the
volume encompassed by the 150% isodose line (23, 27,
50). Aronowitz et al. (50) have recommended that boost
HDR BT be given at doses!15 Gy in three to four frac-
tions (!4.5 Gy/fraction) given twice daily. Wound healing
with HDR and LDR BT appears to be similar. A retrospec-
tive comparison of LDR and HDR BT and EBRT Grade
2e4 wound healing complications were 40% in the LDR
cohort and 18% in the HDR cohort ( p 5 0.14), and there
was a trend of decreased severe complications (Grade3e4) in the HDR group (30% LDR vs. 6% HDR;
p 5 0.06) (27).
Other complications include chronic injury to bones and
nerves. Bone fractures are reported in 0e4.5% of cases
treated with BT (23). In the MSKCC randomized trial of
BT vs. surgery alone, there was no significant difference
in bone fracture risk between the two cohorts ( p 5 0.2)
(34). The risk of bone fracture is increased with periosteal
stripping or bone resection.
Chronic neuropathy is reported in 0e10.1%, but overall
it is not believed to be increased by BT (10, 34, 45).
Special considerations
Recurrent cancer after prior EBRT
BT has been described for treatment of recurrent
sarcomas in a previously irradiated field. There is some
controversy as to the benefit of reirradiation. Torres et al.
reported on their retrospective series of WLE with or
without further radiation in 62 patients. Twenty-five
patients underwent WLE alone and 37 WLE and radiation.
Thirty-three of these patients underwent a single-plane BT
implant. Radiation doses were 45e64 Gy. The 5-year DFS
was 65% and LC 51%. Radiation, however, was not associ-
ated with improved LC, and they noted significant toxicity:
80% reoperation rate in the combined cohort vs. 17% with
surgery alone ( p! 0.001). The amputation rate, however,
was 35% in the surgery-only group and 11% in the irradi-
ated group ( p 5 0.05) (59). Catton et al. (60) reported on
25 patients with recurrent sarcoma, 11 underwent conserva-
tive surgery alone, and 10 conservative surgery and irradi-
ation (six cases BT only, one BT and EBRT, three EBRT
only). The mean dose was 49.5 Gy (35e65 Gy). The over-
all LC at 24 months was 91%, but LC was better when radi-
ation therapy was added to the surgery (36% vs. 100%).
Wound healing complications occurred in 60% of the cases.
In spite of the wound healing problems, 70% were ulti-
mately felt to have good functional outcome. Pearlstone
et al. (61) also reported on a series of 26 patients treated
for local recurrence with a mean BT dose of 47.2 Gy. Local
recurrenceefree survival at 5 years was 52% and DFS 33%.
The reoperation rate was only 15%, possible because 50%
of the patients had up-front tissue transfer grafts.
Retroperitoneal sarcoma
Retroperitoneal sarcomas present a major therapeutic
challenge because of the high rate of local recurrence and
the proximity of the OAR, which include the small bowel,
kidneys, liver, stomach, and spinal cord. Radiation therapy
appears to improve LC in patients with retroperitoneal
sarcomas, and it is most commonly given with preoperative
EBRT (62). Intraoperative radiation (IORT), using electron
beam or HDR BT, has been evaluated as a means to
improve LC (63e66). The delivery of IORT is outside
the scope of this article. The success however of IORT
led to evaluations of postoperative BT in this population.
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rience of 46 patients who underwent gross total resection
with 45 Gy preoperative EBRT (41 patients) with or
without postoperative BT boost of 25 Gy (23 patients).
They found BT to the upper abdomen to be associated with
significant toxicity leading to two deaths (4.3%). This led
the authors to restrict the use of BT to only the lower
abdomen (67). Such treatment approaches should be indi-
vidualized to the patient, and their use may depend on
the skill and expertise of the brachytherapist and surgeon.
Plaque and superficial BT
Dural plaque BT for spine or paraspinal sarcomas has
been described by the Massachusetts General Hospital
group using yttrium-90 or phosphorus-32 as a boost to
EBRT (68). They described a technique of designing
specific semi-cylindrical plaques based on dural areas at
risk as measured on preoperative MRI. The plaques are
then placed intraoperatively to deliver 7.5e15 Gy and then
removed. LC was achieved in 22 of 33 patients (66%) with
minimal toxicity.
BT may be used to treat superficial sarcomas such as an-
giosarcomas of the scalp and other sites and for Kaposi
sarcoma (69e71).
Permanent seed implants
Permanent seeds are a recognized BT technique that
may be applicable to sarcomas in selected circumstances,
particularly when target volumes are small such as in cases
of head and neck, central nervous system, or other confined
tumor locations. Iodine-125 (125I) mesh implants as used
for nonesmall cell lung cancer (72) have been described
for various thoracic malignancies (73, 74). There is,
however, no consensus about the applicability of mesh
implants in treatment of STSs.
Pediatrics
The most common pediatric sarcomas are gynecologic
and genitourinary rhabdomyosarcomas and STS (75). In
the pediatric population, BT, where applicable, can be used
to minimize dose to normal tissue to mitigate the long-term
toxicities of radiation, including growth retardation, effects
on organ function, and theoretically decrease the secondary
malignancy risk. Other advantages of BT are the
decreased treatment time and to avoid or minimize the need
for daily sedation. In some cases, it may be used as the only
form of radiation therapy, and in others, it may need to be
combined with EBRT. Both LDR and HDR have been
described in the pediatric literature (44, 76e83). LDR
temporary implants may incorporate the use of low-
energy sources (such as 125I used alone or in combination
with 192Ir) to improve dosimetry and enhance radiation
safety (83). The use of temporary 125I greatly facilitates
radiation protection of family members and healthcarepersonnel who remain in close contact with the pediatric
patient during treatment. The lower tissue penetration char-
acteristics of 125I can also be used to reduce radiation doses
to adjacent organs. HDR BT altogether eliminates radiation
exposure to nurses, family, and other medical personnel
caring for infants and children. Because of the nature of
BT in the pediatric patient, we recommend that BT be per-
formed in centers with the necessary expertise.Discussion
Radiation therapy improves LC in patients undergoing
conservative surgery for STS. Selected cases with favorable
lesions (small [!5 cm] superficial tumors or small deep
tumors) that can be excised with clear margins (O1 cm)
may be treated with surgery alone. Radiation therapy
should be offered to patients with STS who are at risk of
local recurrence. It can be administered as EBRT or BT
or in combination. The advantages of BT are the localized
nature of the radiation and relative dose sparing of the
surrounding tissue. EBRT has the benefit of being able to
encompass large volumes of tissue at risk of recurrence,
and it is not limited by anatomic constraints. The additional
risks of BT are surgical as both BT and EBRT can produce
acute or chronic radiation-induced side effects.
There are no randomized data or consensus on whether
it is preferable to use EBRT alone, BT monotherapy, or BT
as a boost in the various clinical settings described in this
article. The clinician must use the modality or combination
of modalities that are most familiar to the treatment team
and suitable to the patient.
In the MSKCC randomized trial, BT monotherapy was
described as useful for high-grade lesions with favorable
surgical findings. This single-institution study did not
demonstrate a reduction in local recurrence for low-grade
STS, some of which were large and locally recurrent; this
finding has not been reported by other investigators. We
believe, patients with larger (O5 cm), high grade, or incom-
pletely resected disease (microscopic or gross positive
margins) must be treated with sufficient margins and doses
high enough to achieve local tumor control. In this setting,
depending on morbidity and logistic considerations, BT
boost may be preferable to BT alone. In cases of recurrent
cancer, but without previous radiation therapy, it is recom-
mended that BT be used in conjunction with EBRT.
In a noteworthy publication MSKCC used their prospec-
tive BT database to compare BT monotherapy to EBRT
alone in the form of intensity-modulated radiation therapy
(IMRT). Despite having more adverse features including
positive margins in the IMRT cohort, the LC was better
(91% IMRT vs. 81% BT, p 5 0.04) (84). This LC rate in
the IMRT cohort is similar to some studies using a combina-
tion of EBRT and BT (28, 38, 40, 41, 51). The authors
believe that these results merit further investigations that
compare or combine the BT and IMRT.
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BT is a useful component of the treatment of STS. The
radiation oncologist and surgeon must work closely
together to determine the extent of disease and to correctly
place and stabilize the BT catheters for optimal results.
Three-dimensional simulation and treatment planning are
required for defining the clinical treatment volume and to
identify dose constraints to OAR. Depending on the type
and extent of surgery, it is usually advisable to wait several
days to allow wound healing before starting treatment.
LDR, HDR, and PDR are valid source loading alternatives.
There are more clinical outcome studies with LDR, but
HDR offers the potential for improved dosimetry as well
as new and creative dose and fractionations that might
improve therapeutic ratios. Radiation safety is better with
PDR and HDR remote afterloading. The advantages of
BT are a more targeted dose distribution, the low integral
dose, and shorter treatment times. Adjuvant BT monother-
apy is appropriate for lesions of the trunk and extremity
after complete surgical resection with negative margins.
BT alone is also particularly helpful in pediatric and previ-
ously irradiated patients. Other cases, such as large, incom-
pletely resected, or recurrent (not previously irradiated)
lesions, may be best managed with a combination of BT
and EBRT.
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